New MRA Agent Challenges X-Ray Angiography in AIOD
ABLAVAR (gadofosveset trisodium) is a blood pool contrast agent approved for magnetic resonance angiography to evaluate aortoiliac occlusive disease (AIOD) in patients with known or suspected peripheral vascular disease. The unique albumin-binding properties of ABLAVAR make it ideal for vascular imaging allowing multiple images to be obtained using a single, low-dose injection. ABLAVAR enables the visualization of both arterial and venous blood vessels. ABLAVAR is clinically proven to produce high-resolution MRA images, combining both dynamic (first pass) and steady state imaging, resulting in diagnostic accuracy comparable to X-ray angiography, the current standard of care for diagnosing vascular disease such as AIOD.
ABLAVAR is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease. The agent os made by Lantheus Medical Imaging Inc.
For more information: www.radiopharm.com